Double-Pronged CAR-T cells take aim at Hard-to-Treat blood cancers

NCT ID NCT05436509

Recruiting now Disease control Sponsor: Shenzhen Geno-Immune Medical Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new type of immunotherapy called bi-specific CAR-T cells that target two proteins, CD19 and CD79b, found on B cell cancers. The therapy involves collecting a patient's own immune cells, modifying them to recognize and attack cancer cells, and infusing them back. The trial includes people aged 6 months and older with B cell malignancies that express CD19 or CD79b, and aims to evaluate safety and anti-tumor activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bi-4SCAR CD19/79b T cells
What this could lead to: If successful, this could offer a new treatment option for people with B cell cancers that have not responded to other therapies.
What could go wrong: This is an early-phase trial with a small number of participants, so the results may not apply to everyone. CAR-T therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL MALIGNANCIES

Contacts and locations

Locations

Shenzhen Geno-immune Medical Institute
RECRUITING

Shenzhen, Guangdong, 518000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.